The purpose of this study is to assess potential interactions between intravenous (IV)
cocaine and 3 doses of GBR 12909.
This is Phase 1, double-blind, placebo-controlled human laboratory clinical pharmacology
study that will assess the potential interactions between IV cocaine and 3 escalating oral
doses of GBR 12909. The primary objective is to determine safety of GBR 12909 administration
and if there are significant interactions between GBR 12909 treatment concurrent with IV
- Must be within 20% ideal body weight and must weigh at least 45 kg.
- Must understand the study procedures and provide written informed consent.
- Must meet DSM-4 criteria and are non-treatment seeking at time of study.
- Please contact study site for more information